This Article Figures Only Full Text Full Text (PDF) Correction (v49,p1902) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Adriaenssens, T. Articles by Schömig, A. Search for Related Content PubMed PubMed Citation Articles by Adriaenssens, T. Articles by Schömig, A.

LATE-BREAKING CLINICAL TRIAL

Does Addition of Estradiol Improve the Efficacy of a Rapamycin-Eluting Stent?

Results of the ISAR-PEACE Randomized Trial

Deutsches Herzzentrum, Technische Universtität, Munich, Germany.

Manuscript received February 12, 2007; accepted February 16, 2007.

^_* Reprint requests and correspondence: Dr. Julinda Mehilli, Deutsches Herzzentrum, Lazarettstr. 36, 80636 Munich, Germany. (Email: mehilli{at}dhm.mhn.de).

Objectives: This study aimed to assess the efficacy of a rapamycin plus 17-ß-estradiol–eluting stent versus a rapamycin-eluting stent in patients with coronary artery disease.

Background: Estradiol promotes rapid re-endothelialization of coronary stents in animal models, but it is not known whether combining this drug with rapamycin represents an improved drug-eluting stent technology in terms of reduced lumen renarrowing.

Methods: In this randomized study, we enrolled 502 patients with de novo lesions in native coronary arteries who were randomly assigned to receive either a polymer-free, estradiol plus rapamycin-eluting stent (ERES) (n = 252) or a polymer-free, rapamycin-eluting stent (RES) (n = 250). The primary end point was in-stent late lumen loss in the follow-up angiography. Secondary end points were binary angiographic restenosis, target lesion revascularization, combined incidence of death and myocardial infarction, and incidence of stent thrombosis during 1 year after randomization. The study was designed to test for the superiority of the ERES compared with the RES with respect to in-stent late lumen loss.

Results: Late lumen loss (0.52 ± 0.58 mm vs. 0.51 ± 0.58 mm, p = 0.83), the incidence of binary angiographic restenosis (17.6% vs. 16.9%, p = 0.85), the incidence of target lesion revascularization (14.3% vs. 13.2%, p = 0.72), the combined incidence of death and myocardial infarction (7.9% vs. 8.0%, p = 0.98), and the incidence of stent thrombosis (0.8% vs. 1.2%, p = 0.99) were not significantly different between the ERES group and the RES group.

Conclusions: No apparent beneficial effect is obtained by adding estradiol to a polymer-free rapamycin-eluting stent during the first year after the procedure. (The ISAR-PEACE trial; http://clinicaltrials.gov/ct/show/NCT00402636?order=1; NCT00402636 [ClinicalTrials.gov] )

Abbreviations and Acronyms   ARC = Academic Research Consortium   BMS = bare-metal stent(s)   DES = drug-eluting stent(s)   ERES = estradiol plus rapamycin-eluting stent(s)   IVUS = intravascular ultrasound   PCI = percutaneous coronary intervention   RES = rapamycin-eluting stent(s)

This article has been cited by other articles:

				M. C. John, R. Wessely, A. Kastrati, A. Schomig, M. Joner, M. Uchihashi, J. Crimins, S. Lajoie, F. D. Kolodgie, H. K. Gold, et al. Differential Healing Responses in Polymer- and Nonpolymer-Based Sirolimus-Eluting Stents J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 535 - 544. [Abstract] [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2355 - 2369. [Full Text] [PDF]